BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00111566 |
Recruitment Status :
Completed
First Posted : May 24, 2005
Last Update Posted : November 28, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease Myocardial Infarction | Drug: eptifibatide | Phase 4 |
Percutaneous coronary intervention (PCI) is a common treatment for patients with severe ischemic heart disease. In the majority of cases, the potent anti-platelet agent eptifibatide is administered (bolus followed by infusion for 18 hours). The principal reason to use eptifibatide for PCI is to prevent platelet aggregation and the associated ischemia and myocardial infarction (MI). With improved laminar flow following stenting, prolonged infusion of eptifibatide may no longer be necessary. We hypothesize that after successful stenting with good angiographic results, patients can have eptifibatide discontinued immediately without a higher risk of adverse ischemic outcome, i.e. death, MI or unplanned target vessel revascularization (TVR) by 30 days. MI is defined as creatine kinase-MB (CK-MB) concentrations elevated to more than three times the upper limit of normal or new pathologic Q wave as seen on electrocardiograms (ECG). In order to prove this hypothesis, we estimate a sample size of 2,100 patients.
Before embarking on a large-scale clinical trial, we propose a pilot study using serum troponin I elevation as a surrogate end-point. Troponin I is a sensitive biomarker of ischemic injury. The absence of troponin I release following PCI would suggest excellent short and intermediate term prognosis. For the pilot study, we seek to prove the hypothesis that following successful PCI with stenting, an abbreviated regimen of eptifibatide is not inferior to the standard infusion in preventing ischemic injury, defined as troponin I release if baseline value is normal, or as CK-MB more than 3 times upper limit of normal if baseline troponin I is elevated. For this pilot study, we estimate a sample size of 620 patients.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 624 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention |
Study Start Date : | December 2004 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | August 2007 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 18 Hour infusion |
Drug: eptifibatide |
Experimental: 4 hour infusion |
Drug: eptifibatide |
- Ischemic injury is defined as troponin I release by 24 hours when the baseline troponin I is normal or by measuring creatine kinase (CK-MB) when the baseline troponin I is elevated. [ Time Frame: 24 Hours ]
- 30-day all-cause mortality, non-fatal myocardial infarction (MI), and unplanned target vessel revascularization (TVR) [ Time Frame: 30 days ]
- Composite event rate of non-coronary artery bypass graft (CABG) major bleeding, all-cause mortality, non-fatal MI, and urgent TVR at 30 days post PCI. [ Time Frame: 30 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and non-pregnant female subjects
- 18 years of age or older
- Received aspirin, clopidogrel, heparin (unfractionated or low molecular weight [LMW]) and eptifibatide
- Had a successful PCI procedure with at least one stent deployed
- Availability of a hospital bed
Exclusion Criteria:
- Use of alternative anti-thrombin therapy during PCI (e.g. bivalirudin)
- High risk patients:
- Acute ST elevation MI < 48 hours (either direct PCI or rescue PCI)
- Unprotected left main PCI
- Obvious large thrombus on angiography
- Use of rotablation, atherectomy, or thrombectomy devices
- Unsatisfactory PCI results:
- Final thrombolysis in myocardial infarction (TIMI) flow < 3
- High grade dissection (> type B, if not completely resolved at completion of PCI)
- Evident or suspected thrombus
- Distal embolization
- Suboptimal stenting (> 20% residual stenosis)
- Side branch closure (≥ 1.5 mm branch or with associated symptoms)
- Abrupt closure during procedure (if prolonged > 15 min or not resolved at completion of PCI)
- Clinical instability
- Prolonged ischemia during PCI (> 15 min)
- Increased hazard of eptifibatide infusion:
- Unsatisfactory deployment of a closure device (if used)
- Large peri-procedure hematoma making the continuation of eptifibatide hazardous
- Any condition that will increase the hazard of continuing eptifibatide
- Operator discretion
- No informed consent
- Active participation in other research studies (unless with special exemption)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00111566
Canada, British Columbia | |
Vancouver General Hospital | |
Vancouver, British Columbia, Canada, V5Z 1L8 |
Principal Investigator: | Anthony Fung, MB,BS, FRCPC | University of British Columbia |
Responsible Party: | Anthony Fung, MD, Principal Investigator, Cardiology Research UBC |
ClinicalTrials.gov Identifier: | NCT00111566 |
Other Study ID Numbers: |
C04-0359 |
First Posted: | May 24, 2005 Key Record Dates |
Last Update Posted: | November 28, 2013 |
Last Verified: | November 2013 |
Percutaneous Coronary Intervention (PCI) Glycoprotein IIb/IIIa blockade Ischemic complications following PCI |
Coronary Artery Disease Myocardial Infarction Infarction Ischemia Pathologic Processes Necrosis Coronary Disease Myocardial Ischemia |
Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Eptifibatide Platelet Aggregation Inhibitors |